Canopy Growth Nears Acquisition Finish Line Amid Mixed Financial Results

The Canadian cannabis company Canopy Growth is on the verge of finalizing its takeover of MTL Cannabis, a move announced alongside a quarterly earnings report that presented a complex picture of shrinking losses but persistent challenges.

Quarterly Performance: A Tale of Two Segments

For its third fiscal quarter of 2026, ending December 31, 2025, Canopy Growth reported net revenue of CAD $74.5 million, showing little change from the same period a year earlier. A breakdown reveals divergent trajectories across its business units.

The Canadian adult-use market saw an 8% increase to $23 million, fueled by new product lines under the Tweed, 7ACRES, and Claybourne brands. Similarly, the Canadian medical cannabis segment grew by 15% to reach $23 million, a result attributed to a larger base of patients with insurance coverage and higher order volumes. In stark contrast, international revenue collapsed by 31%, primarily due to supply chain disruptions in Europe. However, a sequential quarterly comparison offers a glimmer of recovery, with international sales rising 22% from the previous quarter as shipments to Europe resumed in the latter half of the period.

The company’s gross margin contracted from 32% to 29%, pressured by weaker profitability in both its cannabis operations and its Storz & Bickel segment. Despite this, the net loss was approximately halved year-over-year. The adjusted EBITDA improved to negative $2.9 million, marking the third consecutive quarter of positive movement on this metric. Since March 2025, Canopy has realized annualized cost savings of $29 million.

MTL Acquisition Gains Overwhelming Shareholder Approval

The path to acquiring MTL Cannabis is now clear following a resounding vote by MTL shareholders. At a special meeting held on February 17, an overwhelming 99.97% of the votes cast were in favor of the transaction, with about 89% of eligible shareholders participating. The deal is expected to close before the end of March 2026, pending final court and third-party approvals.

Strategically, the merger is designed to position Canopy as the leading player in Canada’s medical cannabis market. MTL brings substantial financial heft to the union: for the twelve-month period ending September 2025, it generated net revenue of $84 million, a gross margin of 51% before fair value adjustments, and operating cash flow of $11 million. Canopy anticipates annual synergies of approximately $10 million, which it aims to capture within 18 months of closing the acquisition.

Should investors sell immediately? Or is it worth buying Canopy Growth?

Recapitalization Provides a Financial Cushion

Earlier in January 2026, Canopy Growth undertook a significant balance sheet restructuring. The company extended the maturity of all its outstanding debt obligations to at least January 2031. This maneuver bolstered its cash position to CAD $371 million, resulting in a net liquidity figure of $146 million.

As part of this recapitalization, the company issued convertible notes carrying an annual interest rate of 7.5%. These notes are convertible into common shares at a price of CAD $1.83 per share. A mandatory conversion feature will be triggered if the company’s TSX-listed stock closes above CAD $2.75 for ten consecutive trading days.

Structural Challenges and Regulatory Landscape

Despite operational improvements, significant headwinds remain. Over the last twelve months, Canopy’s total losses amounted to CAD $326.6 million, with $78.7 million in cash burned from ongoing operations alone. The stock price fell roughly 60% during 2025, and over a five-year horizon, the decline exceeds 99%.

On the regulatory front, a recent executive order by U.S. President Trump reclassified cannabis from Schedule I to Schedule III under federal law. This shift could potentially grant industry players access to banking services and tax benefits. However, it does not equate to full federal legalization, meaning the U.S. market remains out of reach for Canopy Growth, which is listed on the Nasdaq.

Company leadership is targeting a positive adjusted EBITDA for fiscal year 2027. The feasibility of this timeline hinges critically on the company’s ability to stabilize its margins and successfully integrate MTL Cannabis to deliver the projected synergies.